|Videos|November 28, 2022
Factors in Selecting First-Line Therapy for Patients With Advanced RCC
Author(s)Matthew T. Campbell, MD, MS, Brian I. Rini, MD
Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
Advertisement
Advertisement
Trending on CancerNetwork
1
BNT113/Pembrolizumab Misses PFS End Point in HPV16+ Head and Neck Cancer
2
RYZ101 Improves Progression-Free Survival in Previously Treated GEP-NETs
3
Teclistamab Vs Talquetamab After Relapse on CAR T-Cell Therapy in Multiple Myeloma
4
How Might IMiD Holding Therapy Impact Outcomes in R/R Multiple Myeloma?
5